Collagen Kinase Receptors as Potential Therapeutic Targets in Metastatic Colon Cancer
Marie Lafitte, Audrey Sirvent, Serge Roche

To cite this version:
Marie Lafitte, Audrey Sirvent, Serge Roche. Collagen Kinase Receptors as Potential Therapeutic Targets in Metastatic Colon Cancer. Frontiers in Oncology, Frontiers, 2020, 10, 10.3389/fonc.2020.00125.
hal-02989658

HAL Id: hal-02989658
https://hal.archives-ouvertes.fr/hal-02989658
Submitted on 19 Nov 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Collagen kinase receptors as potential therapeutic targets in metastatic colon cancer

Marie LAFITTE, Audrey SIRVENT* & Serge ROCHE*

CRBM, CNRS, Univ. Montpellier, F-34000, Montpellier France.

*Correspondence: serge.roche@crbm.cnrs.fr; audrey.sirvent@crbm.cnrs.fr

Key words: collagen, extracellular matrix, tumor microenvironment, receptor, tyrosine kinase, colorectal cancer, metastasis, targeted therapy
ABSTRACT

Colorectal cancer (CRC) is one of the leading causes of tumor-related death worldwide. While surgery can cure patients with early stage CRC, the five-year survival rate is only 10% for patients with metastatic disease. Therefore, new anti-metastatic therapies are needed for this cancer. Metastatic spread defines the dissemination of cancer cells with tumor-initiating capacities from the primary tumor and their colonization of distinct organs, mainly the liver, for secondary tumor formation. Although the underlying mechanisms are not fully understood, components of the tumor microenvironment have gained strong interest. Among the known metastatic-promoting factors, collagens are extracellular matrix components that are deposited within the tumor, the tumor microenvironment, and at metastatic site(s), and are recognized to play essential roles during metastasis development. Here, we review recent findings on the metastatic role of the collagen receptors Discoidin Domain Receptors 1 and 2 (DDR1 and DDR2) in CRC and discuss the therapeutic value of targeting these receptor tyrosine kinases in this cancer.
Colorectal cancer (CRC) remains one of the leading causes of malignancy-related death worldwide. While early-stage tumors have good prognosis, the five-year survival rate is lower than 10% for patients with metastatic CRC (Brenner et al., 2014). CRCs are heterogeneous in nature and their development is influenced by specific genetic, epigenetic, and environmental factors (Brenner et al., 2014). The molecular characterization of CRC for therapeutic decision-making has identified four consensus molecular subtypes (CMS 1-4) (Guinney et al., 2015). CMS1 represents hyper-mutated, microsatellite instable (MSI+) tumors with strong immune activation; CMS2 are WNT/MYC-dependent proliferative tumors; CMS3 include KRAS-mutated tumors and tumors with dysregulated metabolism; and CMS4 tumors are characterized by strong stromal infiltration. Targeted therapies have been developed for metastatic CRC (mCRC), but they display moderate clinical effects. For instance, anti-EGFR or -VEGFR agents prolong patient survival by only few months. Moreover, anti-EGFR therapies cannot be used for KRAS-mutated CRC because of systematic innate resistance (Lièvre and Laurent-Puig, 2009; Pohl and Schmiegel, 2016). Similarly, the results obtained with immune checkpoint inhibitors, such as anti-Programmed cell Death 1 (PD1) antibodies, are variable due to poor immune infiltration, except in the CMS1 subtype (Le et al., 2017; Ciardiello et al., 2019). Currently, effective therapies for mCRC remain a challenge.

**Collagens in CRC metastases**

CRC metastatic spread is characterized by dissemination of specific tumor cell clones with tumor-initiating properties primarily to the liver due to venous drainage (Vanharanta and Massagué, 2013). The underlying molecular causes are not well known, but they might not involve additional genetic alterations (Vanharanta and Massagué, 2013). Indeed, CRC dissemination seems to be an early event (i.e. metastatic clones have disseminated before the tumor clinical detection) (Alves et al., 2019; Hu et al., 2019). Metastasis development may be
mainly influenced by aberrant tumor cell communication with specific components of the tumor microenvironment, the immune system, the blood circulation, or the metastatic niche, in line with the seed and soil theory originally formulated by Paget (Hanahan and Weinberg, 2011; Vanharanta and Massagué, 2013). Among the metastatic factors involved in this process, extracellular matrix (ECM) components have gained strong interest. Specifically, collagens, which are the most abundant ECM components, have been involved in tumor progression (Hanahan and Weinberg, 2011; Vanharanta and Massagué, 2013). Aberrant collagen I, IV and XVII protein levels in CRC samples have been associated with worse prognosis and metastasis development (Wei et al., 2017; Xu et al., 2019). Collagens are produced by cancer-associated fibroblasts (CAF), tumor-associated macrophages (TAM) and tumor cells, and are deposited within or around the tumor or at the metastatic niche, mostly via cancer exosomes and TAMs (Afik et al., 2016; Lafitte et al., 2019). Collagen deposition induces tumor stiffness, resulting in enhanced tumor growth, reduced immune infiltration, and metastatic colonization (Brauchle et al., 2018; Xu et al., 2019). Besides their type, the level of collagen architecture (i.e. polymerization, fiber alignment and distribution) also might influence metastatic progression. Mounting evidences indicate that dense and aligned collagen fibers favor cancer cell invasion (Friedl and Wolf, 2003; Lu et al., 2012). Enzymatic remodeling of collagen polymers also is involved in this malignant process. Specifically, well-known collagen modifiers expressed by tumor or stromal cells, such as metalloproteases, collagenases and lysine oxidases, influence collagen architecture by promoting cross-linkage and stabilization of insoluble collagen deposited in tumor tissues, thus enabling CRC progression (Baker et al., 2013; Wei et al., 2017; Xu et al., 2019). Mechanistically, accumulation of collagen fibers induces an integrin-dependent mechanotransduction pathway that involves actin cytoskeleton contraction (Paszek et al., 2005; Levental et al., 2009). Other post-translational modifications of the collagen matrix might contribute to their metastasis-promoting effect, as recently evidenced for Peptidyl
Arginine Deaminase 4 (PAD4) (Yuzhalin et al., 2018). Specifically, PAD packed in tumor-derived exosomes increases the stiffness of collagen fibers deposited in the liver pre-metastatic niche, through conversion of arginine residues into citrullin residues. Stiffened collagen matrix increases the adhesion of CRC cells at the metastatic site, promoting mesenchymal to epithelial transition, and enabling liver metastasis growth.

**The collagen receptors DDR1 and DDR2**

The many different collagen entities detected in the tumor microenvironment suggest the existence of complex, not-yet fully characterized mechanisms that influence tumor progression. For instance, it was suggested that integrins mediate tumor signaling induced by highly cross-linked collagen fibers (Hamidi and Ivaska, 2018), while the tumor-promoting effects of soluble fibrillar collagens are independent from integrin engagement (Gao et al., 2016). This tumor-promoting activity might be mediated by a poorly characterized class of collagen receptors called Discoidin Domain Receptors (DDR) (Valiathan et al., 2012; Leitinger, 2014). DDRs include DDR1 and DDR2 and belong to the receptor tyrosine kinase family (RTK) (Valiathan et al., 2012; Leitinger, 2014). They are evolutionarily conserved, but they are distinct from the other RTKs due to their capacity to bind to ECM components (Shrivastava et al., 1997; Vogel et al., 1997). DDR1 and DDR2 share highly conserved sequences and a similar modular structure (*i.e.* extracellular domain with binding affinities to collagens, short transmembrane domain, and large cytoplasmic tail containing a kinase domain), but they differ in collagen binding, tissue expression, and signaling. Indeed, DDR1 is activated by most collagen types, including I and IV, which is abundant in the basement membrane. Conversely, DDR2 is only activated by fibrillary collagens, specifically collagen I, III and X (Valiathan et al., 2012; Leitinger, 2014). DDR1 is preferentially expressed in epithelial tissues, whereas DDR2 is expressed in mesenchymal tissues (Valiathan et al., 2012; Leitinger, 2014). Unlike other RTKs,
DDR activation kinetic is slow (detected after 1 hour of collagen stimulation), but sustained over time (more than 1 day). Although the underlying mechanism is not fully understood, it has been proposed that collagen induces the lateral association of DDR1 dimers (i.e. receptor clustering) and phosphorylation between dimers (Coelho et al., 2017; Juskaite et al., 2017; Yeung et al., 2019). Whether DDR2 is activated through a similar mechanism remains unclear (Yeung et al., 2019). Indeed, it was reported that DDR2 activation can be mediated by Src-induced phosphorylation of its activation loop (Ikeda et al., 2002; Yang et al., 2005). DDRs act as a cellular sensor of the ECM microenvironment and can cross-talk with several transmembrane receptors, such as Notch, TGF-β and adhesive receptors, and influence their signaling activity upon collagen deposition (Vogel et al., 2000; Gao et al., 2016). In physiological conditions, DDRs regulate cell polarity, adhesion, migration and proliferation. Knock-out mice showed that DDR1 has a role in mouse mammary gland development, specifically in stromal-epithelial interaction during ductal morphogenesis (Vogel et al., 2001), and that DDR2 acts as an ECM sensor to modulate cell proliferation, required for bone formation (Labrador et al., 2001). However, it is not known whether DDRs have a role in intestinal epithelium development and homeostasis.

**DDR1 in CRC metastases**

DDR1 oncogenic role in human cancers was first highlighted by global phospho-tyrosine profiling in lung cancer (Rikova et al., 2007). Since then, many evidences of an important DDR1 tumor-promoting role in metastasis development have been reported, although this activity may depend on the tumor type and the collagen microenvironment nature. For instance, DDR1 has been involved in the collective migration of squamous cell carcinoma (Hidalgo-Carcedo et al., 2011) and breast tumor cells (Juin et al., 2014), metastatic reactivation in breast cancer (Gao et al., 2016), homing and colonization of lung and bones (Valencia et al.,...
Moreover, in lung cancer, KRAS mutations induce DDR1 expression to sustain tumorigenesis (Jin et al., 2018). We and others (Hu et al., 2014; Jeitany et al., 2018) recently showed that DDR1 promotes CRC cell invasion and metastatic behavior in nude mice, and that its overexpression potentiates these properties. DDR1 also regulates invasiveness of patient-derived cell lines from mCRC and circulating CRC cells, which are at the origin of metastasis development (Jeitany et al., 2018). These studies also suggest that DDR1 acts at different steps of CRC liver metastasis formation (Figure 1). First, in vitro evidence support DDR1 role in local invasion by primary tumor cells and in the invasive properties of disseminated CRC cells, which is essential for metastasis formation. DDR1 activity may then promote CRC cell homing in the liver upon collagen deposition (Figure 1). Finally, DDR1 inhibition displays anti-tumor activity in mice that have already developed DDR1-dependent metastatic nodules, revealing an additional important DDR1 role in metastatic growth (Jeitany et al., 2018). Consistently, DDR1 expression level is associated with shorter overall survival in patients with mCRC, and DDR1 phosphorylation is strongly increased in the corresponding metastatic lesions (Jeitany et al., 2018; Tao et al., 2019). Interestingly, DDR1 upregulation is an independent marker of poor prognosis in patients with stage IV CRC, and is not correlated with any CMS subtype (Jeitany et al., 2018). How DDR1 oncogenic activity is induced in human cancer is not clear, because DDR1 is not frequently mutated. DDR1 upregulation has been linked to oncogenic activation, such as KRAS mutations (Ambrogio et al., 2016), a collagen-dependent amplification loop mechanism, and epigenetic mechanisms. Although all these mechanisms may contribute to DDR1 aberrant expression in CRC, a miRNA-dependent epigenetic mechanism was recently documented in this cancer (Hu et al., 2014; Chen et al., 2019).

Several kinase-dependent and kinase-independent mechanisms by which DDR1 promotes metastatic progression have been reported, depending on the tumor type and/or the
stage of metastasis development. For instance, DDR1 activates, via a kinase-independent mechanism, Tuba and CDC42 to induce early proteolysis-based invasion of breast tumor cells (Juin et al., 2014). By interacting with the tetraspanin TM4SF1, DDR1 recruits PKC alpha to activate JAK2, leading to STAT3 activation for metastatic reactivation (Gao et al., 2016). Conversely, bladder tumor cells colonize airway smooth muscle cells, a rich source of collagen III in lung, via a DDR1 kinase-dependent mechanism, leading to STAT3 transcriptional activation (Lee et al., 2019). Similarly, DDR1 kinase activity is required for K-RAS-driven lung cancer and Notch tumor signaling (Ambrogio et al., 2016). In CRC, we established the central role of DDR1 kinase activity in metastatic progression, as indicated by the loss of such function upon introduction of a kinase-inactive mutation or pharmacological inhibition (Jeitany et al., 2018). By phospho-proteomic analysis of tyrosine phosphorylation, we then revealed that DDR1 acts through a Wnt/β-catenin-dependent and RAS-independent mechanism. Specifically, we identified two unsuspected DDR1 substrates involved in this oncogenic process: the signaling protein Breakpoint Cluster Region (BCR) and the pseudo-kinase PEAK1 of the Pragmin family (Jeitany et al., 2018; Roche et al., 2019). Mechanistically, DDR1 phosphorylation of BCR on tyrosine 177 alleviates a negative regulatory loop on β-catenin signaling to sustain its oncogenic activity, resulting in the induction of genes that are important for tumor cell dissemination and metastasis development, such as MYC, CYCD1 and LGR5 (Ress and Moelling, 2005; Jeitany et al., 2018). Although not investigated in this study, DDR1 may also induce PEAK1 invasive activity (Wang et al., 2010; Huang et al., 2018), possibly via a YAP1-dependent mechanism, as recently suggested (Strnadel et al., 2017). As nuclear YAP1 can form a β-catenin transcription complex that is essential for the transformation and survival of β-catenin-driven cancer (Rosenbluh et al., 2012), we propose that DDR1 supports metastatic development in a collagen-rich environment via a BCR- and PEAK1-dependent mechanism.
**DDR2 in CRC metastases**

The first evidence of DDR2 oncogenic role in human cancer came from its alteration in squamous lung cancer (Hammerman et al., 2011). Afterwards, DDR2 was found to be upregulated in many epithelial malignancies, including breast (Zhang et al., 2013) and ovarian tumors (Grither et al., 2018), and plays a major role in epithelial to mesenchyme transition (EMT) and metastasis development (Zhang et al., 2013; Grither et al., 2018). Mechanistically, DDR2 activity stabilizes the transcription factor and EMT inducer SNA1 (Zhang et al., 2013). DDR2 upregulation in the stroma also may participate in this malignant process by promoting tumor stiffness through integrin-mediated mechanotransduction in CAFs and by promoting stromal-breast cancer cell interaction for metastatic colonization (Corsa et al., 2016; Gonzalez et al., 2017; Bayer et al., 2019). Interestingly, these DDR2 oncogenic activities require a Src-dependent kinase activation mechanism (Zhang et al., 2013). In CRC, evidence for similar DDR2 tumor-promoting functions is lacking. Nevertheless, a recent report suggested that epithelial DDR2 could participate in metastatic progression (Figure 1). Specifically, in a small cohort of patients with CRC, DDR2 level in tumors was associated with high frequency of peritoneal dissemination and poor prognosis (Sasaki et al., 2017). It is unclear whether stromal DDR2 has a similar metastatic role in CRC as in breast tumors. A mouse study suggested that stromal DDR2 deficiency predisposes the hepatic tissue to CRC metastases (Badiola et al., 2012) by fostering trans-differentiation of hepatic stellate cells into myo-fibroblasts for metastatic niche development (Badiola et al., 2012). Whether a similar mechanism operates in human CRC is unknown. Finally, an in vivo functional genomic study using isogenic mouse cancer models to identify genes the inhibition of which potentiates the response to anti-PD1 immunotherapy showed that tumor DDR2 is an essential regulator of MSI+ CRC cell immune evasion (Figure 1) (Tu et al., 2019). Whether DDR2 has a similar role in microsatellite-stable CRC cells remains to be tested. Similarly, it was suggested that DDR1 promotes breast tumor
growth by suppressing the anti-tumor immunity (Zhong et al., 2019). How exactly and in which circumstances DDR1 and DDR2 may regulate human tumor evasion, particularly in CRC, deserve further investigation.

**Targeting DDR tumor activity in metastatic CRC**

All these results suggest that DDR1 and possibly DDR2 are attractive therapeutic targets in mCRC. DDR inhibition could reduce metastasis dissemination or reactivation, and prevent disease relapse (Figure 1). This therapeutic strategy may be particularly relevant for tumors that disseminate at an early stage, as recently suggested for CRC. Moreover, DDR inhibition could reduce metastatic growth, thus facilitating metastatic nodule resection, and also sensitize “cold” tumors to immune checkpoint-based therapies. The fact that DDR1 expression level is not restricted to any specific CMS subclass and that its tumor-promoting function is KRAS mutation-independent suggests that DDR1 inhibitors could be active in all CRC subtypes, including CMS3 tumors for which the therapeutic options are limited. As DDR1 tumor-promoting function in CRC requires its kinase activity, small DDR1 kinase inhibitors might be of therapeutic value. Interestingly, chemical proteomic profiling of several clinical TK inhibitors, including those targeting oncogenic Src or ABL activities, identified DDRs as additional major targets. For instance, DDR1 and DDR2 are inhibited by the anti-leukemic agents nilotinib, bosutinib and dasatinib (IC$_{50}$ in the nM range) (Table 1) (Bantscheff et al., 2007; Rix et al., 2007, 2010). This important observation suggests that DDR inhibition may contribute to the clinical effects of these compounds, and that these inhibitors could be used to target DDR-dependent tumors, including mCRC. We validated this second hypothesis in a preclinical model by showing a strong anti-metastatic activity of nilotinib in DDR1-dependent mCRC cells (Jeitany et al., 2018). The major DDR1 role in this response was demonstrated by the lack of nilotinib activity in CRC cells that express a kinase-dead DDR1 mutant. Similarly,
targeting DDR2 activity with dasatinib enhanced the tumor response to anti-PD1 immunotherapy in a CRC mouse model (Table 1) (Tu et al., 2019). Overall, these results predict that these anti-leukemic agents have also an anti-CRC effect. They could be combined with immune checkpoint inhibitors, particularly in tumors with high DDR level/activity. More recently, several ATP-site inhibitors have been developed to specifically inhibit DDR1 and/or DDR2 activity, and they display significant anti-tumor activities in several cancer models, including CRC cells (Table 1) (Kim et al., 2013; Rammal et al., 2016; Zhavoronkov et al., 2019). As these receptors can also signal through kinase-independent mechanisms, non-kinase inhibitors have been developed to target these tumor-promoting activities. For instance, anti-DDR1 antibodies can interfere with DDR1 binding to collagens, by sterically blocking the extracellular association of DDR1 subunits (Table 1) (Carafoli et al., 2012). Similarly, a neutralizing antibody against DDR1 inhibits breast tumor growth in a mouse model by suppressing the anti-tumor immunity (Zhong et al., 2019). Due to DDR1 aberrant expression in CRC, an anti-DDR1 antibody-drug conjugate was recently developed for CRC treatment. This agent displayed significant anti-tumor activity in a preclinical model of CRC, without overt toxicity in control animals (Table 1) (Tao et al., 2019). Finally, small-molecule allosteric inhibitors of DDR2 extracellular domain inhibit the tumor–microenvironment interaction and breast tumor invasion (Grither and Longmore, 2018). Whether such inhibitor displays similar anti-invasive effect in CRC was not reported.

Conclusion and future directions

Since their discovery more than 20 years ago, the DDR1 and DDR2 collagen receptors are considered critical regulators of cancer invasion. Specifically, they may promote important cancer functions in collagen-rich microenvironments (i.e., cell survival, invasion, cancer stem cell traits and immune evasion) that are required for mCRC development. As a result, these
receptors are becoming attractive therapeutic targets in CRC (Sirvent et al., 2018). However, many important questions remain to be addressed to better understand their roles in CRC and to successfully develop anti-metastatic therapies targeting DDR signaling. First, it will be important to clarify DDR1 and DDR2 respective roles in CRC, specifically in the stromal and tumor compartments. Moreover, as development pathways are often reactivated in cancer, it would be important to address their physiological roles in intestinal homeostasis and regeneration. Due to the complexity of DDR signaling, any kinase-independent function in CRC should be explored because it could have important therapeutic consequence. Similarly, much research is needed to describe the largely unknown DDR1 and DDR2 kinase regulation, and its deregulation in CRC. Although DDR1 upregulation and aberrant tumor collagen deposition are obvious mechanisms, additional mechanisms may be expected. How DDRs induce cancer signaling is another critical question, although we established an important connection between DDR1 signaling and the β-catenin pathway (Jeitany et al., 2018). Last, but not least, recent reports uncovered unsuspected DDR roles in CRC immune evasion (Tu et al., 2019; Zhong et al., 2019). How these receptors contribute to this cancer hallmark is a basic and clinical question because DDR signaling inhibition could define a therapeutic strategy to reduce metastatic development and sensitize CRC to immune checkpoint inhibitors.
**Conflict of interest**

The authors declare no conflict of interest.

**Acknowledgement**

This work was supported by the Association pour la Recherché contre le Cancer ARC, Montpellier SIRIC Grant «INCa-DGOS-Inserm 6045», CNRS, and the University of Montpellier. ML is supported by the Fondation pour la Recherche Médicale (FRM) and the Fondation de France. SR is an INSERM investigator.

**Authors contribution**

SR drafted the first version of the manuscript and ML and AS the figure and the table. All the authors have critically reviewed and approved the manuscript.
References

Afik, R., Zigmond, E., Vugman, M., Klepfish, M., Shimshoni, E., Pasmanik-Chor, M., et al. (2016). Tumor macrophages are pivotal constructors of tumor collagenous matrix. *J. Exp. Med.* 213, 2315–2331. doi:10.1084/jem.20151193.

Alves, J. M., Prado-López, S., Cameselle-Teijeiro, J. M., and Posada, D. (2019). Rapid evolution and biogeographic spread in a colorectal cancer. *Nat. Commun.* 10, 5139. doi:10.1038/s41467-019-12926-8.

Ambrogio, C., Gómez-López, G., Falcone, M., Vidal, A., Nadal, E., Crosetto, N., et al. (2016). Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma. *Nat. Med.* 22, 270–277. doi:10.1038/nm.4041.

Badiola, I., Olaso, E., Crende, O., Friedman, S. L., and Vidal-Vanaclocha, F. (2012). Discoidin domain receptor 2 deficiency predisposes hepatic tissue to colon carcinoma metastasis. *Gut* 61, 1465–1472. doi:10.1136/gutjnl-2011-300810.

Baker, A.-M., Bird, D., Lang, G., Cox, T. R., and Erler, J. T. (2013). Lysyl oxidase enzymatic function increases stiffness to drive colorectal cancer progression through FAK. *Oncogene* 32, 1863–1868. doi:10.1038/onc.2012.202.

Bantscheff, M., Eberhard, D., Abraham, Y., Bastuck, S., Boesche, M., Hobson, S., et al. (2007). Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. *Nat. Biotechnol.* 25, 1035–1044. doi:10.1038/nbt1328.

Bayer, S. V., Grither, W. R., Brenot, A., Hwang, P. Y., Barcus, C. E., Ernst, M., et al. (2019). DDR2 controls breast tumor stiffness and metastasis by regulating integrin mediated mechanotransduction in CAFs. *eLife* 8. doi:10.7554/elife.45508.

Brauchle, E., Kasper, J., Daum, R., Schierbaum, N., Falch, C., Kirschniak, A., et al. (2018). Biomechanical and biomolecular characterization of extracellular matrix structures in human colon carcinomas. *Matrix Biol. J. Int. Soc. Matrix Biol.* 68–69, 180–193. doi:10.1016/j.matbio.2018.03.016.

Brenner, H., Kloor, M., and Pox, C. P. (2014). Colorectal cancer. *Lancet Lond. Engl.* 383, 1490–1502. doi:10.1016/S0140-6736(13)61649-9.

Canning, P., Tan, L., Chu, K., Lee, S. W., Gray, N. S., and Bullock, A. N. (2014). Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors. *J. Mol. Biol.* 426, 2457–2470. doi:10.1016/j.jmb.2014.04.014.

Carafoli, F., Mayer, M. C., Shiraiishi, K., Pecheva, M. A., Chan, L. Y., Nan, R., et al. (2012). Structure of the discoidin domain receptor 1 extracellular region bound to an inhibitory Fab fragment reveals features important for signaling. *Struct. Lond. Engl.* 1993 20, 688–697. doi:10.1016/j.str.2012.02.011.

Chen, L.-Y., Zhi, Z., Wang, L., Zhao, Y.-Y., Deng, M., Liu, Y.-H., et al. (2019). NSD2 circular RNA promotes metastasis of colorectal cancer by targeting miR-199b-5p-mediated DDR1 and JAG1 signalling. *J. Pathol.* 248, 103–115. doi:10.1002/path.5238.

Ciardiello, D., Vitiello, P. P., Cardone, C., Martini, G., Troiani, T., Martinelli, E., et al. (2019). Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy. *Cancer Treat. Rev.* 76, 22–32. doi:10.1016/j.ctrv.2019.04.003.

Coelho, N. M., Arora, P. D., van Putten, S., Boo, S., Petrovic, P., Lin, A. X., et al. (2017). Discoidin Domain Receptor 1 Mediates Myosin-Dependent Collagen Contraction. *Cell Rep.* 18, 1774–1790. doi:10.1016/j.celrep.2017.01.061.

Corsa, C. A. S., Brenot, A., Grither, W. R., Van Hove, S., Loza, A. J., Zhang, K., et al. (2016). The Action of Discoidin Domain Receptor 2 in Basal Tumor Cells and Stromal Cancer-Associated Fibroblasts Is Critical for Breast Cancer Metastasis. *Cell Rep.* 15, 2510–2523. doi:10.1016/j.celrep.2016.05.033.
Day, E., Waters, B., Spiegel, K., Alnadaf, T., Manley, P. W., Buchdunger, E., et al. (2008). Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. *Eur. J. Pharmacol.* 599, 44–53. doi:10.1016/j.ejphar.2008.10.014.

Friedl, P., and Wolf, K. (2003). Tumour-cell invasion and migration: diversity and escape mechanisms. *Nat. Rev. Cancer* 3, 362–374. doi:10.1038/nrc1075.

Gao, H., Chakrabarty, G., Zhang, Z., Akalay, I., Gadiya, M., Gao, Y., et al. (2016). Multi-organ Site Metastatic Reactivation Mediated by Non-canonical Discoidin Domain Receptor 1 Signaling. *Cell* 166, 47–62. doi:10.1016/j.cell.2016.06.009.

Gao, M., Duan, L., Luo, J., Zhang, L., Lu, X., Zhang, Y., et al. (2013). Discovery and optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors. *J. Med. Chem.* 56, 3281–3295. doi:10.1021/jm301824k.

Gonzalez, M. E., Martin, E. E., Anwar, T., Arellano-Garcia, C., Medhora, N., Lama, A., et al. (2017). Mesenchymal Stem Cell-Induced DDR2 Mediates Stromal-Breast Cancer Interactions and Metastasis Growth. *Cell Rep.* 18, 1215–1228. doi:10.1016/j.celrep.2016.12.079.

Grither, W. R., Divine, L. M., Meller, E. H., Wilke, D. J., Desai, R. A., Loza, A. J., et al. (2018). TWIST1 induces expression of discoidin domain receptor 2 to promote ovarian cancer metastasis. *Oncogene* 37, 1714–1729. doi:10.1038/s41388-017-0043-9.

Grither, W. R., and Longmire, G. D. (2018). Inhibition of tumor-microenvironment interaction and tumor invasion by small-molecule allosteric inhibitor of DDR2 extracellular domain. *Proc. Natl. Acad. Sci. U. S. A.* 115, E7786–E7794. doi:10.1073/pnas.1805020115.

Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., et al. (2015). The consensus molecular subtypes of colorectal cancer. *Nat. Med.* 21, 1350–1356. doi:10.1038/nm.3967.

Hamidi, H., and Ivaska, J. (2018). Every step of the way: integrins in cancer progression and metastasis. *Nat. Rev. Cancer* 18, 533–548. doi:10.1038/s41568-018-0038-z.

Hamerman, P. S., Sos, M. L., Ramos, A. H., Xu, C., Dutt, A., Zhou, W., et al. (2011). Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. *Cancer Discov.* 1, 78–89. doi:10.1158/2159-8274.CD-11-0005.

Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of Cancer: The Next Generation. *Cell* 144, 646–674. doi:10.1016/j.cell.2011.02.013.

Hidalgo-Carcedo, C., Hooper, S., Chaudhry, S. I., Williamson, P., Harrington, K., Leitinger, B., et al. (2011). Collective cell migration requires suppression of actomyosin at cell-cell contacts mediated by DDR1 and the cell polarity regulators Par3 and Par6. *Nat. Cell Biol.* 13, 49–58. doi:10.1038/ncb2133.

Hu, Y., Liu, J., Jiang, B., Chen, J., Fu, Z., Bai, F., et al. (2014). MiR-199a-5p loss up-regulated DDR1 aggravated colorectal cancer by activating epithelial-to-mesenchymal transition related signaling. *Dig. Dis. Sci.* 59, 2163–2172. doi:10.1007/s10620-014-3136-0.

Hu, Z., Ding, J., Ma, Z., Sun, R., Seoane, J. A., Scott Shaffer, J., et al. (2019). Quantitative evidence for early metastatic seeding in colorectal cancer. *Nat. Genet.* 51, 1113–1122. doi:10.1038/s41588-019-0423-x.

Huang, L., Wen, C., Yang, X., Lou, Q., Wang, X., Che, J., et al. (2018). PEAK1, acting as a tumor promoter in colorectal cancer, is regulated by the EGFR/KRas signaling axis and miR-181d. *Cell Death Dis.* 9, 271. doi:10.1038/s41419-018-0320-8.

Ikeda, K., Wang, L.-H., Torres, R., Zhao, H., Olaso, E., Eng, F. J., et al. (2002). Discoidin domain receptor 2 interacts with Src and Shc following its activation by type I collagen. *J. Biol. Chem.* 277, 19206–19212. doi:10.1074/jbc.M201078200.
Jeitany, M., Leroy, C., Tosti, P., Lafitte, M., Guet, J. L., Simon, V., et al. (2018). Inhibition of DDR1-BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer. EMBO Mol. Med. 10, e7918. doi:10.15252/emmm.201707918.

Jin, H., Ham, I.-H., Oh, H. J., Bae, C. A., Lee, D., Kim, Y.-B., et al. (2018). Inhibition of Discoidin Domain Receptor 1 Prevents Stroma-Induced Peritoneal Metastasis in Gastric Carcinoma. Mol. Cancer Res. MCR 16, 1590–1600. doi:10.1158/1541-7786.MCR-17-0710.

Juin, A., Di Martino, J., Leitinger, B., Henriet, E., Gary, A.-S., Paysan, L., et al. (2014). Discoidin domain receptor 1 controls linear invadosome formation via a Cdc42-Tuba pathway. J. Cell Biol. 207, 517–533. doi:10.1083/jcb.201404079.

Juskaite, V., Corcoran, D. S., and Leitinger, B. (2017). Collagen induces activation of DDR1 through lateral dimer association and phosphorylation between dimers. eLife 6. doi:10.7554/eLife.25716.

Kim, H.-G., Tan, L., Weisberg, E. L., Liu, F., Canning, P., Choi, H. G., et al. (2013). Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor. ACS Chem. Biol. 8, 2145–2150. doi:10.1021/cb400430t.

Labrador, J. P., Azcoitia, V., Tuckermann, J., Lin, C., Olaso, E., Mañes, S., et al. (2001). The collagen receptor DDR2 regulates proliferation and its elimination leads to dwarfism. EMBO Rep. 2, 446–452. doi:10.1093/embo-reports/kve094.

Lafitte, M., Lecointre, C., and Roche, S. (2019). Roles of exosomes in metastatic colorectal cancer. Am. J. Physiol. Cell Physiol. 317, C869–C880. doi:10.1152/ajpcell.00218.2019.

Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., et al. (2017). Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409–413. doi:10.1126/science.aan6733.

Lee, Y.-C., Kurtova, A. V., Xiao, J., Nikolos, F., Hayashi, K., Tramel, Z., et al. (2019). Collagen-rich airway smooth muscle cells are a metastatic niche for tumor colonization in the lung. Nat. Commun. 10, 2131. doi:10.1038/s41467-019-09878-4.

Leitinger, B. (2014). Discoidin domain receptor functions in physiological and pathological conditions. Int. Rev. Cell Mol. Biol. 310, 39–87. doi:10.1016/B978-0-12-800180-6.00002-5.

Levental, K. R., Yu, H., Kass, L., Lakins, J. N., Egeblad, M., Erler, J. T., et al. (2009). Matrix cross-linking forces tumor progression by enhancing integrin signaling. Cell 139, 891–906. doi:10.1016/j.cell.2009.10.027.

Lièvre, A., and Laurent-Puig, P. (2009). Genetics: Predictive value of KRAS mutations in chemoresistant CRC. Nat. Rev. Clin. Oncol. 6, 306–307. doi:10.1038/nrclinonc.2009.69.

Lu, P., Weaver, V. M., and Werb, Z. (2012). The extracellular matrix: a dynamic niche in cancer progression. J. Cell Biol. 196, 395–406. doi:10.1083/jcb.201102147.

Paszek, M. J., Zahir, N., Johnson, K. R., Lakins, J. N., Rozenberg, G. I., Gefen, A., et al. (2005). Tensional homeostasis and the malignant phenotype. Cancer Cell 8, 241–254. doi:10.1016/j.ccr.2005.08.010.

Patwardhan, P. P., Ivy, K. S., Musi, E., de Stanchina, E., and Schwartz, G. K. (2016). Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma. Oncotarget 7, 4093–4109. doi:10.18632/oncotarget.6547.

Pohl, M., and Schmiegel, W. (2016). Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow. Dig. Dis. Basel Switz. 34, 574–579. doi:10.1159/000445267.

Rammal, H., Saby, C., Magnien, K., Van-Gulick, L., Garnotel, R., Buache, E., et al. (2016). Discoidin Domain Receptors: Potential Actors and Targets in Cancer. Front. Pharmacol. 7. doi:10.3389/fphar.2016.00055.
Ress, A., and Moelling, K. (2005). Bcr is a negative regulator of the Wnt signalling pathway. *EMBO Rep.*, 6, 1095–1100. doi:10.1038/sj.embor.7400536.

Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., et al. (2007). Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. *Cell* 131, 1190–1203. doi:10.1016/j.cell.2007.11.025.

Rix, U., Hantschel, O., Dünnerberger, G., Rix, L. L. R., Planyavsky, M., Fernbach, N. V., et al. (2007). Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. *Blood* 110, 4055–4063. doi:10.1182/blood-2007-07-102061.

Rix, U., Remsing Rix, L. L., Terker, A. S., Fernbach, N. V., Hantschel, O., Planyavsky, M., et al. (2010). A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells. *Leukemia* 24, 44–50. doi:10.1038/leu.2009.228.

Roche, S., Lecointre, C., Simon, V., and Labesse, G. (2019). SHEDding light on the role of Pragmin pseudo-kinases in cancer. *Am. J. Cancer Res.* 9, 449–454.

Rosenbluh, J., Nijhawan, D., Cox, A. G., Li, X., Neal, J. T., Schafer, E. J., et al. (2012). β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. *Cell* 151, 1457–1473. doi:10.1016/j.cell.2012.11.026.

Sasaki, S., Ueda, M., Iguchi, T., Kaneko, M., Nakayama, H., Watanabe, T., et al. (2017). DDR2 Expression Is Associated with a High Frequency of Peritoneal Dissemination and Poor Prognosis in Colorectal Cancer. *Anticancer Res.* 37, 2587–2591. doi:10.21873/anticancerres.11603.

Shrivastava, A., Radziejewski, C., Campbell, E., Kovac, L., McGlynn, M., Ryan, T. E., et al. (1997). An orphan receptor tyrosine kinase family whose members serve as nonintegrin collagen receptors. *Mol. Cell* 1, 25–34. doi:10.1016/s1097-2765(00)80004-0.

Sirvent, A., Lafitte, M., and Roche, S. (2018). DDR1 inhibition as a new therapeutic strategy for colorectal cancer. *Mol. Cell. Oncol.* 5, e1465882. doi:10.1080/23723556.2018.1465882.

Stahtea, X. N., Roussidis, A. E., Kanakis, I., Tzanakakis, G. N., Chalkiadakis, G., Mavroudis, D., et al. (2007). Imatinib inhibits colorectal cancer cell growth and suppresses stromal-induced growth stimulation, MT1-MMP expression and pro-MMP2 activation. *Int. J. Cancer* 121, 2808–2814. doi:10.1002/ijc.23029.

Strnadl, J., Choi, S., Fujimura, K., Wang, H., Zhang, W., Wyse, M., et al. (2017). eIF5A-PEAK1 Signaling Regulates YAP1/TAZ Protein Expression and Pancreatic Cancer Cell Growth. *Cancer Res.* 77, 1997–2007. doi:10.1158/0008-5472.CAN-16-2594.

Tan, F. H., Putoczki, T. L., Lou, J., Hinde, E., Hollandie, F., Giraud, J., et al. (2018). Ponatinib Inhibits Multiple Signaling Pathways Involved in STAT3 Signaling and Attenuates Colorectal Tumor Growth. *Cancers* 10. doi:10.3390/cancers10120526.

Tao, Y., Wang, R., Lai, Q., Wu, M., Wang, Y., Jiang, X., et al. (2019). Targeting of DDR1 with antibody-drug conjugates has antitumor effects in a mouse model of colon carcinoma. *Mol. Oncol.* 13, 1855–1873. doi:10.1002/1878-0261.12520.

Tu, M. M., Lee, F. Y. F., Jones, R. T., Kimball, A. K., Saravia, E., Graziano, R. F., et al. (2019). Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy. *Sci. Adv.* 5, eaav2437. doi:10.1126/sciadv.aav2437.

Valencia, K., Ormazábal, C., Zandueta, C., Luis-Ravelo, D., Antón, I., Pajares, M. J., et al. (2012). Inhibition of collagen receptor discoidin domain receptor-1 (DDR1) reduces cell survival, homing, and colonization in lung cancer bone metastasis. *Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.* 18, 969–980. doi:10.1158/1078-0432.CCR-11-1686.
Valiathan, R. R., Marco, M., Leitinger, B., Kleer, C. G., and Fridman, R. (2012). Discoidin domain receptor tyrosine kinases: new players in cancer progression. *Cancer Metastasis Rev.* 31, 295–321. doi:10.1007/s10555-012-9346-z.

Vanharanta, S., and Massagué, J. (2013). Origins of Metastatic Traits. *Cancer Cell* 24, 410–421. doi:10.1016/j.ccr.2013.09.007.

Vogel, W., Brakebusch, C., Fässler, R., Alves, F., Ruggiero, F., and Pawson, T. (2000). Discoidin domain receptor 1 is activated independently of beta(1) integrin. *J. Biol. Chem.* 275, 5779–5784. doi:10.1074/jbc.275.8.5779.

Vogel, W. F., Aszódi, A., Alves, F., and Pawson, T. (2001). Discoidin domain receptor 1 tyrosine kinase has an essential role in mammary gland development. *Mol. Cell. Biol.* 21, 2906–2917. doi:10.1128/MCB.21.8.2906-2917.2001.

Vogel, W., Gish, G. D., Alves, F., and Pawson, T. (1997). The discoidin domain receptor tyrosine kinases are activated by collagen. *Mol. Cell* 1, 13–23. doi:10.1016/s1097-2765(00)80003-9.

Wang, Y., Kelber, J. A., Tran Cao, H. S., Cantin, G. T., Lin, R., Wang, W., et al. (2010). Pseudopodium-enriched atypical kinase 1 regulates the cytoskeleton and cancer progression [corrected]. *Proc. Natl. Acad. Sci. U. S. A.* 107, 10920–10925. doi:10.1073/pnas.0914776107.

Wei, B., Zhou, X., Liang, C., Zheng, X., Lei, P., Fang, J., et al. (2017). Human colorectal cancer progression correlates with LOX-induced ECM stiffening. *Int. J. Biol. Sci.* 13, 1450–1457. doi:10.7150/ijbs.21230.

Xu, S., Xu, H., Wang, W., Li, S., Li, H., Li, T., et al. (2019). The role of collagen in cancer: from bench to bedside. *J. Transl. Med.* 17, 309. doi:10.1186/s12967-019-2058-1.

Yang, K., Kim, J. H., Kim, H. J., Park, I.-S., Kim, I. Y., and Yang, B.-S. (2005). Tyrosine 740 phosphorylation of discoidin domain receptor 2 by Src stimulates intramolecular autophosphorylation and Shc signaling complex formation. *J. Biol. Chem.* 280, 39058–39066. doi:10.1074/jbc.M506921200.

Yeung, D. A., Shanker, N., Sohail, A., Weiss, B. A., Wang, C., Wellmerling, J., et al. (2019). Clustering, Spatial Distribution, and Phosphorylation of Discoidin Domain Receptors 1 and 2 in Response to Soluble Collagen I. *J. Mol. Biol.* 431, 368–390. doi:10.1016/j.jmb.2018.11.015.

Yuzhalin, A. E., Gordon-Weeks, A. N., Tognoli, M. L., Jones, K., Markec, B., Konietzny, R., et al. (2018). Colorectal cancer liver metastatic growth depends on PAD4-driven citrullination of the extracellular matrix. *Nat. Commun.* 9, 4783. doi:10.1038/s41467-018-07306-7.

Zhang, K., Corsa, C. A., Ponik, S. M., Prior, J. L., Piwnica-Worms, D., Eliceiri, K. W., et al. (2013). The collagen receptor discoidin domain receptor 2 stabilizes SNAIL1 to facilitate breast cancer metastasis. *Nat. Cell Biol.* 15, 677–687. doi:10.1038/ncb2743.

Zhavoronkov, A., Ivanenkov, Y. A., Aliper, A., Veselov, M. S., Aladinskiy, V. A., Aladinskaya, A. V., et al. (2019). Deep learning enables rapid identification of potent DDR1 kinase inhibitors. *Nat. Biotechnol.* 37, 1038–1040. doi:10.1038/s41587-019-0224-x.

Zhong, X., Zhang, W., and Sun, T. (2019). DDR1 promotes breast tumor growth by suppressing antitumor immunity. *Oncol. Rep.* 42, 2844–2854. doi:10.3892/or.2019.7338.
| Molecule                  | IC₅₀ DDR1 (nM) | IC₅₀ DDR2 (nM) | Biological effects in CRC                                                                 | References                                                                 |
|---------------------------|----------------|----------------|------------------------------------------------------------------------------------------|---------------------------------------------------------------------------|
| Multi-kinase inhibitor    |                |                |                                                                                          |                                                                           |
| Dasatinib (BMS-354825)    | 0.5            | 1.4            | Enhances the anti-tumor response of anti-PD1 in a CRC mouse model                          | (Day et al., 2008; Tu et al., 2019)                                       |
| Imatinib (STI571)         | 337            | 675            | Inhibits CRC cell growth and stromal-induced growth stimulation                           | (Stahtea et al., 2007; Day et al., 2008)                                   |
| Nilotinib (AMN107)        | 43             | 55             | Inhibits CRC cells invasion and metastatic development in nude mice                       | (Day et al., 2008; Jeitany et al., 2018)                                   |
| Ponatinib (AP24534)       | 9              | 9              | Inhibits CRC cell migration Inhibits CRC tumor growth in nude mice                         | (Canning et al., 2014; Tan et al., 2018)                                  |
| Bafetinib (INNO-406)      | n/a            | 220            | n/a                                                                                      | (Rix et al., 2010)                                                        |
| Sitravatinib (MGCD516)    | 29             | 0.5            | n/a                                                                                      | (Patwardhan et al., 2016)                                                 |
| DDRs kinase inhibitor     |                |                |                                                                                          |                                                                           |
| Compound 1                | 10             | 234            | n/a                                                                                      | (Zhavoronkov et al., 2019)                                                |
| Compound 2                | 21             | 76             | n/a                                                                                      | (Zhavoronkov et al., 2019)                                                |
| Compound 4                | 279            | 162            | n/a                                                                                      | (Zhavoronkov et al., 2019)                                                |
| WRG-28                    | -              | 230            | n/a                                                                                      | (Grither and Longmore, 2018)                                               |
| DDR1-IN-1                 | 105            | 413            | Inhibits CRC cells growth                                                                 | (Kim et al., 2013)                                                        |
| DDR1-IN-2                 | 47             | 143            | Inhibits CRC cells growth                                                                 | (Kim et al., 2013)                                                        |
| 7rh                       | 6,8            | 101,4          | n/a                                                                                      | (Gao et al., 2013)                                                        |
| 7rj                       | 7              | 93,6           | n/a                                                                                      | (Gao et al., 2013)                                                        |
| DDR1 antibody             |                |                |                                                                                          |                                                                           |
| T4H11-DM4 antibody        | n/a            | -              | Inhibits CRC tumor growth in nude mice                                                   | (Tao et al., 2019)                                                        |
| mAb 3E3                   | n/a            | -              | n/a                                                                                      | (Carafoli et al., 2012)                                                   |
| Neutralizing DDR1 antibody| n/a            | -              | n/a                                                                                      | (Zhong et al., 2019)                                                      |

Table 1: anti-tumor activity of DDRs inhibitors/antibodies in CRC.
**Figure legend**

**Figure 1: Proposed DDR1 and DDR2 functions during metastasis development of CRC.**

DDR1 and DDR2 activation upon collagen deposition may promote local CRC cell invasion from the primary tumor, through invadosomes formation and epithelial cell migration, and immune evasion enabling cell dissemination; CRC cells lodging at the metastatic site for CRC cells survival; metastatic reactivation (micrometastases) and development (macrometastases). Note that DDRs functions reported in other tumor-types and to be confirmed in CRC are indicated with a question-mark. Immune cells and collagens deposition around the tumor or at the metastatic niche are indicated.
Primary tumor

**DDR1**
- Micrometastases
- Liver
- Homing
- Metastatic growth
- Distant dissemination
- Local dissemination
- Immune escape

**DDR2**
- Micrometastases
- Macrometastases
- Liver
- Immune escape

Collagens

**Immune escape**